Publications

Journal Article
Review
Epublish 47 citations
Electronic publication date
October 12, 2022

View on Pubmed.gov 36209124 | View on doi.org 10.1186/s12967-...

Recent developments in the probiotics as live biotherapeutic products (LBPs) as modulators of gut brain axis related neurological conditions.

Search for publications in this journal J Transl Med - 20(1):460

Abstract

Probiotics have been defined as "living microorganisms that create health benefits in the host when taken in sufficient amounts. Recent developments in the understanding of the relationship between the microbiom and its host have shown evidence about the promising potential of probiotics to improve certain health problems. However, today, there are some confusions about traditional and new generation foods containing probiotics, naming and classifications of them in scientific studies and also their marketing. To clarify this confusion, the Food and Drug Administration (FDA) declared that it has made a new category definition called "live biotherapeutic products" (LBPs). Accordingly, the FDA has designated LBPs as "a biological product that: i)contains live organisms, such as bacteria; ii)is applicable to the prevention, treatment, or cure of a disease/condition of human beings; and iii) is not a vaccine". The accumulated literature focused on LBPs to determine effective strains in health and disease, and often focused on obesity, diabetes, and certain diseases like inflammatory bowel disease (IBD).However, microbiome also play an important role in the pathogenesis of diseases that age day by day in the modern world via gut-brain axis. Herein, we discuss the novel roles of LBPs in some gut-brain axis related conditions in the light of recent studies. This article may be of interest to a broad readership including those interested in probiotics as LBPs, their health effects and safety, also gut-brain axis.

References

Sci Rep. 2017 Oct 19;7(1):13537

Neurosci Biobehav Rev. 2021 Sep;128:549-557

Neurobiol Stress. 2020 Mar 20;12:100216

Clin Nutr. 2019 Apr;38(2):522-528

Cited by 47 citations (total)

Journal Article Review

Gut Microbiota and Immunotherapy for Alzheimer's Disease.

Electronic publication date December 15, 2022

Search for publications in this journal Int J Mol Sci

Chun-Ling Dai [...] Cheng-Xin Gong et al.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that eventually leads to dementia and death of the patient. Currently, no...

Journal Article

Multi-omics analyses of Bacillus amyloliquefaciens treated mice infected with Schistosoma japonicum reveal dynamics change of intestinal microbiome and its associations with host metabolism.

Electronic publication date October 28, 2024

Search for publications in this journal PLoS Negl Trop Dis

Hao Chen [...] Zheng Yu et al.

BACKGROUND

Schistosomiasis japonica is a serious threat to human health. It causes damage to the intestine and liver. Probiotic therapy has...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

© 2022. The Author(s).